SARS-CoV-2 vaccines: fast track versus efficacy.
作者信息
Alkandari Dana, Herbert Jenny A, Alkhalaf Moustafa A, Yates Carol, Panagiotou Stavros
机构信息
Division of Medical Education, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PT, UK.
出版信息
Lancet Microbe. 2021 Mar;2(3):e89-e90. doi: 10.1016/S2666-5247(21)00034-3. Epub 2021 Feb 9.
Abstract
摘要
相似文献
1
SARS-CoV-2 vaccines: fast track versus efficacy.
Lancet Microbe. 2021 Mar;2(3):e89-e90. doi: 10.1016/S2666-5247(21)00034-3. Epub 2021 Feb 9.
2
COVID-19 vaccines and decreased transmission of SARS-CoV-2.
Inflammopharmacology. 2021 Oct;29(5):1357-1360. doi: 10.1007/s10787-021-00847-2. Epub 2021 Jul 19.
3
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.
4
Special focus 'SARS-CoV-2 / COVID-19: advances in developing vaccines and immunotherapeutics'.
Hum Vaccin Immunother. 2020 Dec 1;16(12):2888-2890. doi: 10.1080/21645515.2020.1847952.
5
Talk of the town in 2021: Covid-19 vaccines likely take centre stage.
Scand J Immunol. 2021 Jan;93(1):e13014. doi: 10.1111/sji.13014.
6
Safety of mRNA-Based Vaccines for SARS CoV-2.
Chem Res Toxicol. 2021 Aug 16;34(8):1823-1825. doi: 10.1021/acs.chemrestox.1c00129. Epub 2021 May 19.
7
Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.
JAMA. 2021 Jan 19;325(3):221-222. doi: 10.1001/jama.2020.25127.
8
Migraine treatment and COVID-19 vaccines: No cause for concern.
Headache. 2021 Mar;61(3):409-411. doi: 10.1111/head.14086.
9
Covid-19 vaccines for teenagers: conversations and consent.
BMJ. 2021 Sep 22;374:n2312. doi: 10.1136/bmj.n2312.
10
COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic.
Anaesthesia. 2021 Apr;76(4):435-443. doi: 10.1111/anae.15365. Epub 2020 Dec 14.
引用本文的文献
1
Political Affiliation, Policy Measures, and Intention to Receive COVID-19 and Influenza Vaccines.
Int J Environ Res Public Health. 2024 Nov 30;21(12):1608. doi: 10.3390/ijerph21121608.
2
The outcome and related risk factors of unvaccinated patients with end-stage kidney disease during the Omicron pandemic: a multicentre retrospective study.
BMJ Open. 2024 May 15;14(5):e084649. doi: 10.1136/bmjopen-2024-084649.
3
Effectiveness of vaccination in reducing hospitalization and mortality rates in dialysis patients with Omicron infection in China: A single-center study.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2252257. doi: 10.1080/21645515.2023.2252257.
4
Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review.
Vaccines (Basel). 2023 Feb 16;11(2):452. doi: 10.3390/vaccines11020452.
5
Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses.
Iran J Basic Med Sci. 2022 May;25(5):554-561. doi: 10.22038/IJBMS.2022.63527.14015.
6
Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
BMC Infect Dis. 2022 Jul 13;22(1):610. doi: 10.1186/s12879-022-07593-y.
7
COVID-19 vaccine: A 2021 analysis of perceptions on vaccine safety and promise in a U.S. sample.
PLoS One. 2022 May 19;17(5):e0268784. doi: 10.1371/journal.pone.0268784. eCollection 2022.
8
Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems.
Pharmaceutics. 2022 Apr 13;14(4):856. doi: 10.3390/pharmaceutics14040856.
9
Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection.
Infect Drug Resist. 2022 Apr 15;15:1871-1887. doi: 10.2147/IDR.S360103. eCollection 2022.
10
Affordable IgY-based antiviral prophylaxis for resource-limited settings to address epidemic and pandemic risks.
J Glob Health. 2022 Feb 26;12:05009. doi: 10.7189/jogh.12.05009. eCollection 2022.
本文引用的文献
1
Looking beyond COVID-19 vaccine phase 3 trials.
Nat Med. 2021 Feb;27(2):205-211. doi: 10.1038/s41591-021-01230-y. Epub 2021 Jan 19.
2
Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination.
BMJ. 2021 Jan 15;372:n149. doi: 10.1136/bmj.n149.
3
SARS-CoV-2 vaccines in development.
Nature. 2020 Oct;586(7830):516-527. doi: 10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
4
Developing Covid-19 Vaccines at Pandemic Speed.
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
5
Combating vaccine hesitancy and other 21st century social determinants in the global fight against measles.
Curr Opin Virol. 2020 Apr;41:1-7. doi: 10.1016/j.coviro.2020.01.001. Epub 2020 Feb 26.
6
Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases.
Clin Pharmacol Ther. 2020 Feb;107(2):324-332. doi: 10.1002/cpt.1627. Epub 2019 Oct 11.
7
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
Front Immunol. 2019 Apr 16;10:751. doi: 10.3389/fimmu.2019.00751. eCollection 2019.
8
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study.
Lancet Glob Health. 2018 Dec;6(12):e1386-e1396. doi: 10.1016/S2214-109X(18)30346-2. Epub 2018 Oct 18.
9
Rotarix: a rotavirus vaccine for the world.
Clin Infect Dis. 2009 Jan 15;48(2):222-8. doi: 10.1086/595702.
Zotero 插件